Shares of MannKind Corporation (NASDAQ:MNKD) ended Friday session in green amid volatile trading. The shares closed up +0.005 points or 0.71% at $0.740 with 5.26 million shares getting traded. Post opening the session at $0.75, the shares hit an intraday low of $0.72 and an intraday high of $0.82 and the price vacillated in this range throughout the day. The company has a market cap of $324.87 million and the numbers of outstanding shares have been calculated to be 478.05 million shares.
MannKind Corporation (MNKD) announced that it will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 11:40 AM (ET) at the Lotte New York Palace in New York.
Presenting from the Company will be its Chief Executive Officer, Matthew J. Pfeffer.
Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company’s website at http://www.mannkindcorp.com.
Shares of Array Biopharma Inc (NASDAQ:ARRY) ended Friday session in red amid volatile trading. The shares closed down -0.02 points or -0.57% at $3.50 with 1.19 million shares getting traded. Post opening the session at $3.54, the shares hit an intraday low of $3.41 and an intraday high of $3.54 and the price vacillated in this range throughout the day. The company has a market cap of $520.90 million and the numbers of outstanding shares have been calculated to be 145.02 million shares.
Array Biopharma Inc (ARRY) on Sept. 1, 2016 announced that the FDA has accepted its New Drug Application (NDA) for binimetinib with a target action date under the Prescription Drug User Fee Act (PDUFA) of June 30, 2017. Array completed its NDA submission of binimetinib in late June 2016 based on findings from the pivotal Phase 3 NEMO (NRAS MELANOMA AND MEK INHIBITOR) trial in patients with NRAS-mutant melanoma. The FDA also indicated that it plans to hold an advisory committee meeting (ODAC) as part of the review process. As previously reported, Array is currently preparing for an Application Orientation Meeting (AOM) with the FDA in September 2016, which it expects will include a discussion of the NDA package including clinical risk / benefit.
“There are very few treatment advances beyond immunotherapy for this devastating disease, which impacts one out of five advanced melanoma patients,” said Victor Sandor, M.D., Chief Medical Officer, Array BioPharma. “Binimetinib is the first and only MEK inhibitor to demonstrate improvement on progression free survival in a Phase 3 trial for NRAS mutant melanoma patients.”